Acetophenone protection against cisplatin-induced end-organ damage

Brian Geohagen, Elizabeth Zeldin, Kimberly Reidy, Tao Wang, Evripidis Gavathiotis, Yonatan I. Fishman, Richard LoPachin, David M. Loeb, Daniel A. Weiser

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Cisplatin is a widely used and efficacious chemotherapeutic agent for treating solid tumors, yet it causes systemic end-organ damage that is often irreversible and detrimental to quality of life. This includes severe sensorineural hearing loss, hepatotoxicity, and renal injury. Based on the hard-soft acid-base theory, we recently developed two acetophenone-derived, enol-based compounds that directly interfere with the side effects of cisplatin. We investigated organ-specific and generalized toxicity in order to define dose-dependent responses in rodents injected with cisplatin with or without the protective compounds. All metrics that were used as indicators of toxicity showed retention of baseline or control measurements when animals were pre-treated with acetophenones prior to cisplatin administration, while animals injected with no protective compounds showed expected elevations in toxicity measurements or depressions in measurements of organ function. These data support the further investigation of novel acetophenone compounds for the prevention of cisplatin-induced end-organ toxicity.

Original languageEnglish (US)
Article number101595
JournalTranslational Oncology
StatePublished - Jan 2023


  • Acetophenone
  • Cisplatin
  • End-organ damage
  • Hepatotoxicity
  • Nephrotoxicity
  • Ototoxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Acetophenone protection against cisplatin-induced end-organ damage'. Together they form a unique fingerprint.

Cite this